Menopausal hormone therapy and mortality: A systematic review and meta-analysis

Khalid Benkhadra, Khaled Mohammed, Alaa Al Nofal, Barbara G. Carranza Leon, Fares Alahdab, Stephanie Faubion, Victor Manuel Montori, Abd Moain Abu Dabrh, Jorge Alberto Zúñiga Hernández, Larry J. Prokop, Mohammad H Murad

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: The objective was to assess the effect of menopausal hormonal therapy (MHT) on all-cause and cause-specific mortality. Methods: We conducted a comprehensive search of several databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus) from inception until August 2013. We included randomized controlled trials (RCTs) of more than 6 months of duration comparing MHT with no treatment. Pairs of independent reviewers selected trials, assessed risk of bias and extracted data. We estimated risk ratios (RRs) and 95% confidence intervals (CIs) using the random-effects model. Results:Weincluded 43 RCTs at moderate risk of bias. Meta-analysis showed no effect on mortality (RR 0.99[95%CI, 0.94-1.05]), regardless ofMHTtype or history of preexisting heart disease.Noassociation was found between MHT and cardiac death (RR 1.04 [95% CI 0.87-1.23]) or stroke (RR 1.49 [95% CI 0.95-2.31]). Estrogen plus progesterone use was associated with a likely increase in breast cancer mortality (RR 1.96[95%CI 0.98-3.94]),whereasestrogen usewasnot.MHTusewasnot associated with mortality of other types of cancer. In 5 trials,MHTwaslikely started at a younger age: 2 RCTs withmean agelessthan60and3RCTswithMHTstarted lessthan10years aftermenopause.Meta-analysis of these 5 RCTs showed a reduction of mortality with MHT (RR 0.70 [95% CI 0.52-0.95]). Conclusion: The current evidence suggests that MHT does not affect the risk of death from all causes, cardiac death and death from stroke or cancer. These data may be used to support clinical and policy deliberations about the role of MHT in the care of symptomatic postmenopausal women.

Original languageEnglish (US)
Pages (from-to)4021-4028
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume100
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Meta-Analysis
Hormones
Odds Ratio
Confidence Intervals
Mortality
Randomized Controlled Trials
Therapeutics
Stroke
Databases
Preexisting Condition Coverage
MEDLINE
Progesterone
Cause of Death
Heart Diseases
Neoplasms
Estrogens
Breast Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Benkhadra, K., Mohammed, K., Al Nofal, A., Carranza Leon, B. G., Alahdab, F., Faubion, S., ... Murad, M. H. (2015). Menopausal hormone therapy and mortality: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 100(11), 4021-4028. https://doi.org/10.1210/jc.2015-2238

Menopausal hormone therapy and mortality : A systematic review and meta-analysis. / Benkhadra, Khalid; Mohammed, Khaled; Al Nofal, Alaa; Carranza Leon, Barbara G.; Alahdab, Fares; Faubion, Stephanie; Montori, Victor Manuel; Abu Dabrh, Abd Moain; Hernández, Jorge Alberto Zúñiga; Prokop, Larry J.; Murad, Mohammad H.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 100, No. 11, 01.11.2015, p. 4021-4028.

Research output: Contribution to journalArticle

Benkhadra, K, Mohammed, K, Al Nofal, A, Carranza Leon, BG, Alahdab, F, Faubion, S, Montori, VM, Abu Dabrh, AM, Hernández, JAZ, Prokop, LJ & Murad, MH 2015, 'Menopausal hormone therapy and mortality: A systematic review and meta-analysis', Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 11, pp. 4021-4028. https://doi.org/10.1210/jc.2015-2238
Benkhadra K, Mohammed K, Al Nofal A, Carranza Leon BG, Alahdab F, Faubion S et al. Menopausal hormone therapy and mortality: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2015 Nov 1;100(11):4021-4028. https://doi.org/10.1210/jc.2015-2238
Benkhadra, Khalid ; Mohammed, Khaled ; Al Nofal, Alaa ; Carranza Leon, Barbara G. ; Alahdab, Fares ; Faubion, Stephanie ; Montori, Victor Manuel ; Abu Dabrh, Abd Moain ; Hernández, Jorge Alberto Zúñiga ; Prokop, Larry J. ; Murad, Mohammad H. / Menopausal hormone therapy and mortality : A systematic review and meta-analysis. In: Journal of Clinical Endocrinology and Metabolism. 2015 ; Vol. 100, No. 11. pp. 4021-4028.
@article{de97c18827be49129617957ed3d794e8,
title = "Menopausal hormone therapy and mortality: A systematic review and meta-analysis",
abstract = "Objectives: The objective was to assess the effect of menopausal hormonal therapy (MHT) on all-cause and cause-specific mortality. Methods: We conducted a comprehensive search of several databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus) from inception until August 2013. We included randomized controlled trials (RCTs) of more than 6 months of duration comparing MHT with no treatment. Pairs of independent reviewers selected trials, assessed risk of bias and extracted data. We estimated risk ratios (RRs) and 95{\%} confidence intervals (CIs) using the random-effects model. Results:Weincluded 43 RCTs at moderate risk of bias. Meta-analysis showed no effect on mortality (RR 0.99[95{\%}CI, 0.94-1.05]), regardless ofMHTtype or history of preexisting heart disease.Noassociation was found between MHT and cardiac death (RR 1.04 [95{\%} CI 0.87-1.23]) or stroke (RR 1.49 [95{\%} CI 0.95-2.31]). Estrogen plus progesterone use was associated with a likely increase in breast cancer mortality (RR 1.96[95{\%}CI 0.98-3.94]),whereasestrogen usewasnot.MHTusewasnot associated with mortality of other types of cancer. In 5 trials,MHTwaslikely started at a younger age: 2 RCTs withmean agelessthan60and3RCTswithMHTstarted lessthan10years aftermenopause.Meta-analysis of these 5 RCTs showed a reduction of mortality with MHT (RR 0.70 [95{\%} CI 0.52-0.95]). Conclusion: The current evidence suggests that MHT does not affect the risk of death from all causes, cardiac death and death from stroke or cancer. These data may be used to support clinical and policy deliberations about the role of MHT in the care of symptomatic postmenopausal women.",
author = "Khalid Benkhadra and Khaled Mohammed and {Al Nofal}, Alaa and {Carranza Leon}, {Barbara G.} and Fares Alahdab and Stephanie Faubion and Montori, {Victor Manuel} and {Abu Dabrh}, {Abd Moain} and Hern{\'a}ndez, {Jorge Alberto Z{\'u}{\~n}iga} and Prokop, {Larry J.} and Murad, {Mohammad H}",
year = "2015",
month = "11",
day = "1",
doi = "10.1210/jc.2015-2238",
language = "English (US)",
volume = "100",
pages = "4021--4028",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Menopausal hormone therapy and mortality

T2 - A systematic review and meta-analysis

AU - Benkhadra, Khalid

AU - Mohammed, Khaled

AU - Al Nofal, Alaa

AU - Carranza Leon, Barbara G.

AU - Alahdab, Fares

AU - Faubion, Stephanie

AU - Montori, Victor Manuel

AU - Abu Dabrh, Abd Moain

AU - Hernández, Jorge Alberto Zúñiga

AU - Prokop, Larry J.

AU - Murad, Mohammad H

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objectives: The objective was to assess the effect of menopausal hormonal therapy (MHT) on all-cause and cause-specific mortality. Methods: We conducted a comprehensive search of several databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus) from inception until August 2013. We included randomized controlled trials (RCTs) of more than 6 months of duration comparing MHT with no treatment. Pairs of independent reviewers selected trials, assessed risk of bias and extracted data. We estimated risk ratios (RRs) and 95% confidence intervals (CIs) using the random-effects model. Results:Weincluded 43 RCTs at moderate risk of bias. Meta-analysis showed no effect on mortality (RR 0.99[95%CI, 0.94-1.05]), regardless ofMHTtype or history of preexisting heart disease.Noassociation was found between MHT and cardiac death (RR 1.04 [95% CI 0.87-1.23]) or stroke (RR 1.49 [95% CI 0.95-2.31]). Estrogen plus progesterone use was associated with a likely increase in breast cancer mortality (RR 1.96[95%CI 0.98-3.94]),whereasestrogen usewasnot.MHTusewasnot associated with mortality of other types of cancer. In 5 trials,MHTwaslikely started at a younger age: 2 RCTs withmean agelessthan60and3RCTswithMHTstarted lessthan10years aftermenopause.Meta-analysis of these 5 RCTs showed a reduction of mortality with MHT (RR 0.70 [95% CI 0.52-0.95]). Conclusion: The current evidence suggests that MHT does not affect the risk of death from all causes, cardiac death and death from stroke or cancer. These data may be used to support clinical and policy deliberations about the role of MHT in the care of symptomatic postmenopausal women.

AB - Objectives: The objective was to assess the effect of menopausal hormonal therapy (MHT) on all-cause and cause-specific mortality. Methods: We conducted a comprehensive search of several databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus) from inception until August 2013. We included randomized controlled trials (RCTs) of more than 6 months of duration comparing MHT with no treatment. Pairs of independent reviewers selected trials, assessed risk of bias and extracted data. We estimated risk ratios (RRs) and 95% confidence intervals (CIs) using the random-effects model. Results:Weincluded 43 RCTs at moderate risk of bias. Meta-analysis showed no effect on mortality (RR 0.99[95%CI, 0.94-1.05]), regardless ofMHTtype or history of preexisting heart disease.Noassociation was found between MHT and cardiac death (RR 1.04 [95% CI 0.87-1.23]) or stroke (RR 1.49 [95% CI 0.95-2.31]). Estrogen plus progesterone use was associated with a likely increase in breast cancer mortality (RR 1.96[95%CI 0.98-3.94]),whereasestrogen usewasnot.MHTusewasnot associated with mortality of other types of cancer. In 5 trials,MHTwaslikely started at a younger age: 2 RCTs withmean agelessthan60and3RCTswithMHTstarted lessthan10years aftermenopause.Meta-analysis of these 5 RCTs showed a reduction of mortality with MHT (RR 0.70 [95% CI 0.52-0.95]). Conclusion: The current evidence suggests that MHT does not affect the risk of death from all causes, cardiac death and death from stroke or cancer. These data may be used to support clinical and policy deliberations about the role of MHT in the care of symptomatic postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=84958632292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958632292&partnerID=8YFLogxK

U2 - 10.1210/jc.2015-2238

DO - 10.1210/jc.2015-2238

M3 - Article

C2 - 26544652

AN - SCOPUS:84958632292

VL - 100

SP - 4021

EP - 4028

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -